On Thursday, Glenmark Pharmaceuticals Limited announced that it has become the first pharmaceutical company to launch Thiazolidinedione Lobeglitazone (Lobeglitazone) in India. Lobeglitazone is an antidiabetic drug used to treat type 2 diabetes. It works as an insulin sensitizer and helps in making human cells more responsive to insulin.

In India, the drug will be marketed under the brand name LOBG, containing 0.5 mg of lobeglitazone. The drug is to be taken once daily under prescription to improve glycemic control in adult diabetic patients.

Glenmark has received approval from the Indian drug regulator, Drug Controller General of India, for the manufacturing and marketing of Lobeglitazone based on a randomized, double-blind Phase 3 clinical trial conducted on adult Type 2 diabetic patients, aged 18 years and older. The results of the trial have revealed that glycemic control is improved with the use of lobeglitazone.

As a leading solutions provider in India for the treatment of diabetes, Glenmark Pharmaceuticals stated that as a leading solutions provider in India for the treatment of diabetes, the company is proud to introduce LOBG, an innovative and affordable drug, which can help in tackling insulin resistance among adult patients suffering from uncontrolled Type 2 diabetes in the country.